Floatz logo

SIMVASTATIN

Wilms Tumor

Emory UniversitySmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

40 Active assets in the Wilms Tumor cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Centre Oscar Lambret
Phase 2BB
Inno-206
Children's National Research Institute
Phase 2BB
Itraconazole
Samsung Medical Center
Phase 4BB
Irinotecan
Centre Oscar Lambret
Phase 2BB
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

SIMVASTATIN is also rated in:

HypercholesterolemiaDormant
BBB
Indicative ·
76 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
75 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →